BRIEF—Mundipharma and Santen expand partnership in ophthalmology

UK-based Mundipharma has boosted its partnership with Japanese ophthalmic specialist Santen Pharmaceutical.

The deal builds on an existing licence for preservative-free prostaglandin analog Saflutan (tafluprost), adding around 50 new markets in the Middle East and Africa region.

Mundipharma also adds Taptiqom (tafluprost/timolol) to its portfolio for Canada, Australia, New Zealand, Latin America, the Middle East and Africa.

The firm’s chief executive Raman Singh said: "We are delighted to further expand our ophthalmic portfolio as well as our successful partnership with Santen."

“The extended licensing footprint will provide physicians in the additional countries with more preservative-free treatment options for glaucoma patients.”